www.biocompatibles.com
Biocompatibles International plc is a leading company in the field of drug-device combination products. The Oncology Products Division conducts the marketing of Biocompatibles’ approved oncology products. These include products that are used for the treatment of primary liver cancer (HCC), liver metastases from colorectal cancer and prostate cancer. Our R&D Facilities are engaged in licensing and in new product development for oncology, stroke, and diabetes and obesity. We have collaborative agreements with AstraZeneca, Bayer Healthcare Pharmaceuticals Inc. and Medtronic Inc.
Sorry, no articles available.
-
17/12/10
Biocompatibles liver cancer treatment submitted for marketing approval in Japan -
19/11/10
City warms to the merits of BTG takeover of Biocompatibles -
19/11/10
Biocompatibles accepts BTG's £177 mln bid -
28/10/10
Biocompatibles in advanced offer talks and full-year sales on track -
28/10/10
Biocompatibles in advanced offer talks and full-year sales on track -
15/10/10
Biocompatibles partner committed to Novabel sales re-start, but timing unsure -
23/09/10
AstraZeneca and Biocompatibles kick of CM3 trial for Type 2 diabetes -
26/08/10
Biocompatibles International turns profitable in H1, reports positive results from DEBIRI trial -
06/07/10
Biocompatibles buys out bead products patent license for US$4.5m -
24/06/10
Edison Investment Research notes progress at Biocompatibles, supports revenues forecasts -
16/06/10
Biocompatibles forecasts profitability from H1 and raises guidance for full year -
25/03/10
Edison Investment Research discusses Biocompatibles valuation -
18/03/10
The drugs work: Biocompatibles sees further good sales growth ahead -
18/03/10
The drugs work: Biocompatibles sees further good sales growth ahead -
17/02/10
Biocompatibles and AstraZeneca co-developed diabetes drug enters Phase I trial -
09/02/10
Edison Investment Research values Biocompatibles at 360p, awaits results from CM3 AstraZeneca trial -
08/01/10
Biocompatibles Intl says 209 was ‘excellent’ and guides for 13 pct revenue rise in 2010, plans 25 p -
12/10/09
Biocompatibles says institutions raise holdings in company -
07/08/09
Biocompatibles’ China launch of drug-eluting bead product slightly delayed -
28/07/09
Biocompatibles gets milestone payment as Eisai exercises option on Drug-Eluting Beads in Japan -
18/06/09
Biocompatibles says year started well, reiterates full-year sales guidance -
03/06/09
Biocompatibles’ Sir Thopmas Harris invests money from maturing ISA in company shares -
13/05/09
Biocompatibles exec directors opt to receive dividends in company shares -
28/04/09
Biocompatibles reports positive results from liver cancer patient trial -
17/04/09
Biocompatibles first quarter sales ahead of company expectations -
19/03/09
Biocompatibles partner Merz gets CE Mark approval for dermal filler bead Novabel -
06/03/09
Biocompatibles CEO and FD buy further shares in company -
05/03/09
Biocompatibles doubles full-year revenue and slashes losses, plans to pay dividend in May -
18/02/09
Biocompatibles sets back FY results announcement by 2 days to allow presentation -
17/02/09
Biocompatibles treats 1st patient in Drug-Eluting Beads trial on colorectal cancer metastases
Sorry, no media files found.
